XCNQSONA
Market cap19mUSD
Dec 23, Last price
0.27CAD
1D
5.88%
1Q
-6.90%
Jan 2017
800.00%
IPO
58.82%
Name
Sona Nanotech Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
25.54%
Rev. gr., 5y
%
Revenues
0k
Net income
-2m
L+2.21%
CFO
-1m
L-30.18%
Earnings
Apr 25, 2025
Profile
Sona Nanotech Inc., nanotechnology life sciences company, manufactures and sells gold nanorod products for diagnostic tests. The company also provides Nanotech COVID-19 Lateral Flow Assay, an immunochromatographic assay for the detection of the spike protein antigen from SARS-CoV-2 in saliva specimens from individuals, who are suspected of COVID-19; Gemini gold nanorods; Omni gold nanorods for medical applications; and contract services. Its products are used in various applications, including drug delivery, food and beverage testing, environmental testing, cell imaging, cancer treatment, and liposuction therapy, as well as medical and consumer, military, and veterinary diagnostics. The company is based in Halifax, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | 2015‑10 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 1,498 | 3,118 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,498) | (3,118) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (41) | 84 | |||||||
Tax Rate | |||||||||
NOPAT | (1,457) | (3,203) | |||||||
Net income | (2,500) 2.21% | (2,446) -77.29% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,011 | 585 | |||||||
BB yield | -6.74% | -5.90% | |||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | 528 | 608 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 412 | 444 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (1,260) | (1,805) | |||||||
CAPEX | |||||||||
Cash from investing activities | 15 | ||||||||
Cash from financing activities | 1,200 | ||||||||
FCF | (625) | (3,142) | |||||||
| Balance | |||||||||
Cash | 115 | 164 | |||||||
Long term investments | |||||||||
Excess cash | 115 | 164 | |||||||
Stockholders' equity | (1,483) | (4,619) | |||||||
Invested Capital | 3,173 | 4,720 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 85,752 | 68,408 | |||||||
Price | 0.18 20.69% | 0.15 -56.06% | |||||||
Market cap | 15,007 51.29% | 9,919 -53.07% | |||||||
EV | 15,419 | 10,363 | |||||||
EBITDA | (1,042) | (3,058) | |||||||
EV/EBITDA | |||||||||
Interest | 68 | 84 | |||||||
Interest/NOPBT | |||||||||